Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $87M. The Maz Rating grades it against the other companies in its sector.
Cumberland Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.80, Cumberland Pharmaceuticals Inc. trades at 1.2x trailing earnings, 3.3x sales and 1.2x book value. Over the last twelve months it generated about $26M of revenue and $71M of net income. It runs a gross margin of 79.0%, an operating margin of -38.2% and a net margin of 275.0%. It shows return on equity of 202.6%, return on invested capital of -12.0% and a free cash flow yield of -1.2%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 3.05. Over the past 52 weeks the share price ranged from $1.85 to $9.28, with a beta of 0.10.
Cumberland Pharmaceuticals Inc. pays a dividend yielding 26.71%, with 33% of earnings paid out.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cumberland Pharmaceuticals Inc. (CPIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 78.9% / 30% · Interest income / Revenue 38.2% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 78.9% / 33% · Receivables / Mkt Cap (36m) 22.6% / 49% · Interest income / Revenue 38.2% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 78.9% / 33.33% · Receivables / Mkt Cap (24m) 22.6% / 33.33% · Interest income / Revenue 38.2% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.38% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 32.9% / 33.33% · Receivables / Avg Assets (4Q) 20.9% / 33.33% · Interest income / Revenue 38.2% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 70.8% / 33.33% · (Cash+Recv) / Total Assets 91.1% / 33.33% · Interest income / Revenue 38.2% / 5% | Fail |
No. As of September 2026, Cumberland Pharmaceuticals Inc. (CPIX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cumberland Pharmaceuticals Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 38.2% of each dividend: Cumberland Pharmaceuticals Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.